This new French-Mediterranean restaurant from a luxury brand has Brickell buzzing
Now open a little south of Komodo and just a bit north of RosaNegra on Brickell Avenue is Riviera Dining Group's Claudie, a French and Mediterranean restaurant that finds its inspiration in the South of France.
Led by founder Gregory Galy, the group is also the brains behind Casa Neos, a glamorous waterfront Mediterranean spot that opened along the Miami River in 2024, and Mila, named last year as one of the most beautiful restaurants in the United States by People magazine and OpenTable.
Brickell is the perfect fit for Claudie, Galy said, calling the downtown neighborhood 'one of the city's most dynamic and rapidly growing areas.'
'Brickell is the heartbeat of modern Miami, a vibrant, cosmopolitan neighborhood where luxury, culture and a global culinary scene all come together,' he said. 'It attracts an international crowd that values both sophistication and unique dining experiences. Claudie feels right at home here.'
The restaurant continues the brand's focus on hospitality and entertainment. Designed by OV & Co. and Lazaro Rosa Violan, Claudie offers a 2,408-square-foot indoor dining room with circular lights as its centerpiece (it's meant, not surprisingly, to evoke the sun's glow along the Cote d'Azur). There's also a private dining room with a Mediterranean-style mural.
A bar bridges the dining room with the outdoor terrace, which seats 104 diners, with a fountain and greenery all around.
The restaurant's evocation of the South of France is what sets it apart, Galy said.
'It's not just about the food — it's about the entire experience,' he said. 'Every detail is designed to create an atmosphere that feels both intimate and lively.'
The food, however, is also not an afterthought. The Riviera group's head of culinary is Chef Michael Michaelidis, whose career began on the French Riviera and went on to include stints at several Michelin-starred restaurants and work with culinary greats like Alain Ducasse and Joël Robuchon.
One of the restaurant's signature experiences is a twist on the usual table-side Caesar. Instead of Romaine lettuce and lots of cheese, Claudie offers table-side gazpacho service (with or without vodka). Other items include lobster pate, classic escargot, grilled shrimp truffle toupie macaroni and steak frites. There's also a seafood tower packed with shellfish.
The menu may seem elevated (and it is), but Galy sees the restaurant as part of Miami's culinary evolution, a place where diners can slow down and relax as opposed to the high-energy atmosphere of other new upscale restaurants.
'Miami has always been known for its vibrant energy and diverse food culture, but I think there's a growing demand for dining experiences that feel elevated and intimate yet unpretentious,' he said. 'With Claudie, we've captured that balance.'
Claudie
Where: 1101 Brickell Ave., Suite 113
Hours: 6 p.m.-1 a.m. Wednesday-Thursday; 5:30 p.m.-2 a.m. Friday-Sunday; closed Monday and Tuesday
Reservations and more information: claudierestaurant.com or 305-990-1101
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
2 hours ago
- USA Today
PGA Tour CEO in testy exchange with reporter: 'Are you asking a LIV question?'
ATLANTA – New PGA Tour CEO Brian Rolapp can smell a LIV question a mile away. During his press conference on Wednesday ahead of the Tour Championship, he called out a reporter who was attempting to bait him. Reporter: Do you accept the premise that what golf fans want primarily is the best players in the world playing together more often? 'Yeah, I think, yeah, golf fans want to see the best competition possible in the sport that they love in a competitive model that makes sense,' Rolapp answered. Reporter: I think it's been surveyed already they want to see the best players together on a more regular basis. Should that not be a priority for you? 'Are you asking a LIV question?' Rolapp replied. Reporter: Essentially, yes. 'Well, ask a LIV question,' he said. Reporter: I asked. 'Look, I think I'm going to focus on what I can control. I would offer to you that the best collection of golfers in the world are on the PGA Tour. I think there's a bunch of metrics that demonstrate that, from rankings to viewership to whatever you want to pick. I'm going to lean into that and strengthen that,' Rolapp said. 'I will also say that to the extent we can do anything that's going to further strengthen the PGA Tour, we'll do that, and I'm interested in exploring whatever strengthens the PGA Tour.' And so ended that testy exchange. New PGA Tour CEO Brian Rolapp said he hasn't spoken to PIF Earlier in the proceedings, Rolapp, who is just 18 days into the job since joining the Tour from the NFL, where he worked for 22 years, confirmed he hasn't spoken to anyone from the Public Investment Fund. 'I think my primary focus is going to be on strengthening the Tour, and blank sheet of paper means blank sheet of paper. Whatever does that, I'll pursue aggressively. That's how I view it.' He also wouldn't take the bait for a Tour-LIV related question that wondered if he would be inclined to create a Ryder Cup-style match pitting the Tour against LIV. 'Listen, I don't want to answer hypotheticals. What I will say is what I said before. I'm interested in any idea that strengthens the PGA Tour,' he said. 'So any idea that comes, that fits within our competitive model and our objectives for the benefit of our players and our fans, I'm interested in it.'
Yahoo
4 hours ago
- Yahoo
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
NANTES, France, August 20, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the appointment of Thomas Gidoin as Chief Financial Officer. Thomas joins the Executive Committee, bringing over 15 years of deep international expertise in capital markets, financial strategy, and governance to the company. Thomas Gidoin is an experienced biopharma finance executive with a strong track record in strategic financial leadership, both in private and public companies. Prior to joining OSE Immunotherapeutics, he served as Chief Financial Officer at Advesya, a privately held Franco-Swiss clinical-stage biotech company in oncology and autoimmune diseases, after having spent 8 years as CFO of GenSight Biologics, a Euronext-listed French biopharma company developing gene therapies for neurodegenerative retinal diseases, where he led the company's financing strategy from the Series B to the IPO on Euronext Paris and a number of follow-on transactions and structured financings. Previously, Thomas was Vice President of Finance at DBV Technologies, where he led the Corporate Finance team and contributed to public offerings and private placements, including the dual listing of the company on the US NASDAQ. Prior to this, Thomas served as Northern Europe Business Controller at PregLem in London, held several positions at Ipsen, including UK Operations Controller in London and Senior Financial Analyst in the Global Operations division in Paris. He started his career in audit at Ernst & Young in Paris. He holds master's degrees in international finance from ESGF Paris and in international management from NEOMA Business School. Thomas succeeds Anne-Laure Autret-Cornet, marking a new phase in the company's financial leadership. Nicolas Poirier, Chief Executive Officer, OSE Immunotherapeutics, commented: 'Thomas joins OSE Immunotherapeutics with deep experience in biotech capital markets financing and strategic financial planning. He has a clear understanding of what it takes to support innovation through disciplined execution and rigorous cash management. His arrival comes at a time when financial leadership is key to advancing our two late-stage assets and continuing to leverage our research platform. His expertise will further reinforce the management team to prepare the next phase of growth with clarity and focus.' Thomas Gidoin, Chief Financial Officer, OSE Immunotherapeutics, said: 'I am thrilled to join OSE Immunotherapeutics at such a pivotal moment in its journey. With two late-stage assets in oncology and inflammation, boosted by a highly innovative research platform, the company is well positioned to create meaningful long-term value through clear multiple short-term inflexion points. I look forward to working closely with the leadership team to help unlock the full potential of OSE's innovative pipeline.' ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on LinkedInContacts Fiona Dé Contact Media France: FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 Contact Media US:RooneyPartners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachments EN_2508_20_CFO_vf EN_2508_20_CFO_vf
Eater
6 hours ago
- Eater
How I Tripled Restaurant Sales by Streamlining the Lunch Rush
A version of this post originally appeared on August 20, 2025, in Eater and Punch's newsletter Pre Shift, a biweekly newsletter for the industry pro that sources first-person accounts from the bar and restaurant world. This send is the final in a three-part series on high-volume restaurants, presented by Square — the technology company that makes commerce and financial services easy and accessible. Amba, according to Cambridge Street Hospitality Group chef and owner Will Gilson Where: Cambridge, Massachusetts The backstory: James Beard Award semifinalist Will Gilson launched Cambridge Street Hospitality Group in 2012 and now operates eight concepts in Cambridge, Massachusetts. In 2024, he opened his most recent restaurant, Amba, at a local farmers market. In the first year of business, the Mediterranean-inspired fast-casual restaurant has almost tripled its daily sales. Gilson discusses how he got here. On staffing during peak hours I wish I could tell you that there's a perfect science behind it, but sometimes we just try to make sure that we're not overstacking ourselves. We have one person on the line to get everything open in the morning to cook breakfast. To prepare for our busiest hours, we add another person on the line at about 10:30 a.m. and another at noon. Between catering and in-house orders and stuff that's hitting the delivery services, we're doing up to 400 items. On encouraging online orders Now people are really used to ordering their food online ahead of time and picking it up, which [keeps] the queue of people [from getting too busy]. We don't have the infrastructure of Starbucks or Dunkin' as far as their online ordering goes, but everything from our website to our Square site prompts people to be able to do that. Most of [our customers] are placing their orders ahead of time. We also have two [self-service] kiosks that we have set up inside. On the kiosks, we have a sign that says, 'Don't want to wait in line, use this kiosk right here.' That's a way to direct people if there is a queue that is forming. Staffers working the line at Amba. Lisa Nichols On the efficiency of premade ingredients Coming from a chef background, I was thinking about making absolutely everything ourselves. What ended up helping us grow faster was identifying two of the items that we were going to be using the most—pita and hummus—and trying to see if we could find the best vendor that we could that could supply us with those. I'm sure I could make a better hummus than the one that we get, but it would take forever [between soaking, boiling, blending, and storing]—and it would require a system that is so complicated that maybe only a couple people could do it. We're paying a little bit of a premium to be able to have somebody else's product. Daily, we're probably saving five hours of labor. On strategically opening new locations I have been able to go from one restaurant to eight concepts in the past five years. I always [want to] make sure that we're walking into the right deal. A lot of the brands that get acquired by venture capital end up going into high-profile spaces with very high rent as a way for marketing. Owning this ourselves without that sort of investment means that those deals are less attractive to us. [We consider factors like] foot traffic and parking. If so much of your food is going out the door via delivery apps, then you need to make sure that you're in a space where people aren't having to park far away. You [also] want to avoid scooters and bicycles and Uber cars just clogging up the front of your business. Customers eating at the Cambridge location. Lisa Nichols We want to make sure that we don't grow too fast until we really understand the nuance of the demand [we're supplying]. We spent a lot of time trying to find a concept where we can hit the right price points; [at Amba,] there's nothing on the menu that costs over $20. We felt as though this was the type of concept that would fit into this neighborhood where there are a lot of offices and residences, and not a place that was known for sit-down dining. In all the years that we've been doing this, we've never opened up a concept that made the people so happy so quickly. I'm never confident that any restaurant will work, but you take a leap of faith. This interview has been condensed and edited for clarity.
